February 25, 2014
PSC’s Dr. Bruce Van Natta of Indianapolis, Indiana interviews Valérie Taupin, founder and CEO of Teoxane Laboratories from Geneva, Switzerland to discuss the cosmetic line and dermal filler product that’s making its way to the U.S.
New Wrinkle Filler Popular in Europe
Alphaeon Corporation, a wholly owned subsidiary of Strathspey Crown Holdings, has acquired an exclusive United States license for Geneva-based TEOXANE Laboratories’ full line of cosmeceuticals and hyaluronic acid-based dermal filler products. “During the past 10 years, TEOXANE has gained significant market presence and leadership in Europe, capturing the number two market position in several western European countries for its broad range of next-generation hyaluronic acid dermal fillers and innovative cosmeceuticals,” says Robert E. Grant, CEO of Alphaeon.
Teoxane Laboratories was created in 2003. “We are in 80 countries, and have produced over 4 million syringes that have been injected,” says Taupin. Using hyaluronic acid in all their wrinkle fillers, Taupin says these products are 100% absorbable and of non-animal origin. Teoxane’s cosmetic line is also formulated with a hyaluronic acid base. “When in contact with the skin, hyaluronic acid microspheres lodge in the hollows of wrinkles and furrows. They act as mini water sensors, to swell up and smooth the skin. This non-invasive filling is almost immediate,” says Taupin. “Physicians in the United States have been asking us to bring our innovative products to the U.S. market for many years,” says Taupin. Once these products receive FDA approval, expect to see them at your plastic surgeons office.